Basal Plus GLP1-ra on Glycemic Variability in CKD

Exclusion Criteria

• •1. Type 1 diabetes
• •2. Currently pregnant, as demonstrated by a positive pregnancy test at screening or planning pregnancy
• •3. Treatment with GLP-1 RA or insulin degludec in the past three months
• •4. Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study.
• •5. Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff.
• •6. Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.
• •7. Extensive skin changes/diseases that preclude wearing the CGM on normal skin at the proposed application sites (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis).
• •8. Have a known allergy to medical-grade adhesives
• •9. Known current or recent alcohol or drug abuse
• •10. Diabetic ketoacidosis, hyperosmolar hyperglycaemic state or myocardial infarction in the six months prior to screening
• •11. Patients on renal replacement therapy or likely require kidney transplant or dialysis during the study period
• •12. Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection.
• •13. An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).